Emergent BioSolutions (EBS) Capital Expenditures Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 32.98% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -21.54% |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | -33.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.33% |
| Dec 31, 2025 | -111.76% |
| Sep 30, 2025 | -181.03% |
| Jun 30, 2025 | -76.03% |
| Mar 31, 2025 | 9.09% |
| Dec 31, 2024 | -95.99% |
| Sep 30, 2024 | 131.52% |
| Jun 30, 2024 | -38.89% |
| Mar 31, 2024 | -57.69% |
| Dec 31, 2023 | 151.21% |
| Sep 30, 2023 | -165.95% |
| Jun 30, 2023 | -38.32% |
| Mar 31, 2023 | -75.78% |
| Dec 31, 2022 | -514.00% |
| Sep 30, 2022 | 188.01% |
| Jun 30, 2022 | 4,112.50% |
| Mar 31, 2022 | -0.92% |
| Dec 31, 2021 | 306.19% |
| Sep 30, 2021 | 36.09% |
| Jun 30, 2021 | -102.28% |